337 related articles for article (PubMed ID: 16315008)
1. Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci.
Eliopoulos GM
Eur J Clin Microbiol Infect Dis; 2005 Dec; 24(12):826-31. PubMed ID: 16315008
[TBL] [Abstract][Full Text] [Related]
2. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents.
Hsueh PR; Chen WH; Teng LJ; Luh KT
Int J Antimicrob Agents; 2005 Jul; 26(1):43-9. PubMed ID: 15975769
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
[TBL] [Abstract][Full Text] [Related]
4. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
5. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
Sader HS; Watters AA; Fritsche TR; Jones RN
BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
[TBL] [Abstract][Full Text] [Related]
6. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
Ardura MI; Mejías A; Katz KS; Revell P; McCracken GH; Sánchez PJ
Pediatr Infect Dis J; 2007 Dec; 26(12):1128-32. PubMed ID: 18043450
[TBL] [Abstract][Full Text] [Related]
7. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: emerging problems and new prospects for management.
Noskin GA
Ann Acad Med Singap; 2001 May; 30(3):320-31. PubMed ID: 11455748
[TBL] [Abstract][Full Text] [Related]
8. Treatment of infections caused by resistant Staphylococcus aureus.
Anstead GM; Quinones-Nazario G; Lewis JS
Methods Mol Biol; 2007; 391():227-58. PubMed ID: 18025681
[TBL] [Abstract][Full Text] [Related]
9. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
Napolitano LM
Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
[TBL] [Abstract][Full Text] [Related]
10. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
Scheinfeld N
J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167
[TBL] [Abstract][Full Text] [Related]
11. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of daptomycin against isolates of Staphylococcus aureus and enterococci: first results from Turkey.
Arslan H; Azap OK; Ergin F; Karaman SO; Oruç E
Int J Antimicrob Agents; 2004 Jun; 23(6):642-3. PubMed ID: 15194140
[No Abstract] [Full Text] [Related]
13. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
Micek ST
Clin Infect Dis; 2007 Sep; 45 Suppl 3():S184-90. PubMed ID: 17712745
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial resistance among gram-positive organisms in the intensive care unit.
Clark NM; Hershberger E; Zervosc MJ; Lynch JP
Curr Opin Crit Care; 2003 Oct; 9(5):403-12. PubMed ID: 14508154
[TBL] [Abstract][Full Text] [Related]
15. New bisanthraquinone antibiotics and semi-synthetic derivatives with potent activity against clinical Staphylococcus aureus and Enterococcus faecium isolates.
Socha AM; LaPlante KL; Rowley DC
Bioorg Med Chem; 2006 Dec; 14(24):8446-54. PubMed ID: 16979896
[TBL] [Abstract][Full Text] [Related]
16. [Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)].
Loza E; Morosini MI; Pascual A; Tubau F; Alcalá J; Liñares J; Hernández-Bello JR; Baquero F; Perea E; Martín R; Jones RN; Cantón R;
Enferm Infecc Microbiol Clin; 2008 Oct; 26(8):489-94. PubMed ID: 19094861
[TBL] [Abstract][Full Text] [Related]
17. Tedizolid as Step-Down Therapy following Daptomycin versus Continuation of Daptomycin against Enterococci and Methicillin- and Vancomycin-Resistant Staphylococcus aureus in a Rat Endocarditis Model.
Singh KV; Arias CA; Murray BE
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32122892
[TBL] [Abstract][Full Text] [Related]
18. New antimicrobial agents as therapy for resistant gram-positive cocci.
Lentino JR; Narita M; Yu VL
Eur J Clin Microbiol Infect Dis; 2008 Jan; 27(1):3-15. PubMed ID: 17899228
[TBL] [Abstract][Full Text] [Related]
19. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations.
Brauers J; Kresken M; Menke A; Orland A; Weiher H; Morrissey I
Int J Antimicrob Agents; 2007 Mar; 29(3):322-5. PubMed ID: 17204403
[TBL] [Abstract][Full Text] [Related]
20. Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria.
Eliopoulos GM
J Infect; 2009 Sep; 59 Suppl 1():S17-24. PubMed ID: 19766885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
